Pherexa
WebBetter health is on the way. PHAREX’s humble beginnings can be traced back to 1973. It first started as a subsidiary of Pascual Laboratories as the company’s exclusive marketing, … Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy. Ander Urruticoechea , Mohammed Rizwanullah , Seock-Ah Im , Antonio Carlos Sánchez Ruiz
Pherexa
Did you know?
Webthe final analysis of OS in PHEREXA was consistent with the interim OS analysis4 and supports clinical activity of H + P being maintained with longer follow-up. • INV-PFS was consistent with the primary analysis,4 with median of 9.0 months in the H + X arm and 11.8 months in the H + X + P arm. WebMar 22, 2024 · HR for overall survival was only calculated in CLEOPATRA (0.86), PHEREXA (0.76), and PRECIOUS (0.71). Based on these results, “a pertuzumab-based dual HER2 blockade regimen could be a...
WebSep 10, 2024 · Purpose To assess the efficacy and safety of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2 … WebPHEREXA Capecitabine + Trastuzumab +/- Pertuzumab Trastuzumab plus Pertuzumab no sign. difference in PFS (Urruticoechea, et al. ASCO 2016,Abstract 504.) Prior Trastuzumab and Lapatinib TH3RESA T-DM1 vs. Physician Treatment of Choice (PTC) T-DM1 sign. improvement in PFS and OS (Krop, et al. Lancet Oncol 2014.)
WebAs commented before, the use of trastuzumab and pertuzumab in trastuzumab-resistant patients has been explored in phase II studies. 17,18,24 Based on the promising activity of … WebMay 20, 2016 · PHEREXA: A phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy …
WebJul 7, 2016 · PHEREXA was a randomized trial looking at the addition of a drug called pertuzumab. 1 Pertuzumab is an anti-HER2 antibody, and it has been shown to have great benefit in the first-line setting of metastatic breast cancer. When used in the first line-setting, it extends survival substantially when added to trastuzumab, the standard drug, plus a ...
WebMay 4, 2024 · The PHEREXA trial, published in the current issue of JCO, investigated the addition of pertuzumab to trastuzumab plus capecitabine in the second-line metastatic setting after prior therapy with chemotherapy and trastuzumab.The primary endpoint, improved PFS, was not met from a statistical sense; the median PFS improvement from 9 … new intel computer stickWebMay 30, 2024 · We present exploratory efficacy results from pts treated with T-DM1 any time after P from 2 phase III studies: CLEOPATRA and PHEREXA. Methods: CLEOPATRA (NCT00567190) and PHEREXA (NCT01026142) are randomized, 2-arm trials evaluating P-based regimens for HER2+ MBC. new intel cpu rumorsWebOct 15, 2015 · In my opinion, of greatest interest will be the upcoming data of these two monoclonal antibodies in combination with endocrine therapy, and the results of the PHEREXA trial, a randomized study that will define the role of pertuzumab with trastuzumab and capecitabine in patients progressing on trastuzumab-based therapy. new intel cpus without kpti vulnerabilityWebSep 21, 2016 · The PHEREXA study was for patients who were being treated in the second-line setting and progressed after a taxane- and trastuzumab-based treatment. The … new intel cpu coolerWebMar 15, 2013 · The role of pertuzumab in the second-line setting will be addressed by results of the PHEREXA trial. The continuation of HER2 blockade remains an important component of therapy at disease progression, and therapy with lapatinib or novel agents available through clinical trials should be considered. Data from the EMILIA trial showed that T … new intel compute stickWebNov 20, 2024 · However, despite the formal negative results of the PHEREXA trial, a clinically relevant activity of trastuzumab plus pertuzumab in pretreated patients can be assumed. Conclusion Results of clinical trials and translational research projects presented at the ASCO annual meeting 2024 extend our knowledge of the treatment and biology of ... in the same timeWebgas. dizziness. headache. excessive tiredness. difficulty falling asleep or staying asleep. joint pain. pain, redness, hardness, swelling, irritation, itching, bruising, bleeding, … in the same time用法